IRIS
FAVOINO, ELVIRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.082
EU - Europa 2.428
AS - Asia 1.949
SA - Sud America 518
Continente sconosciuto - Info sul continente non disponibili 278
AF - Africa 91
OC - Oceania 1
Totale 10.347
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.916
RU - Federazione Russa 834
SG - Singapore 758
IT - Italia 757
CN - Cina 455
BR - Brasile 411
HK - Hong Kong 252
SE - Svezia 219
VN - Vietnam 155
DE - Germania 131
FR - Francia 121
FI - Finlandia 91
GB - Regno Unito 90
UA - Ucraina 79
IN - India 61
BD - Bangladesh 59
CA - Canada 57
AR - Argentina 39
ID - Indonesia 38
TR - Turchia 31
MX - Messico 23
PL - Polonia 20
ZA - Sudafrica 20
CI - Costa d'Avorio 18
CO - Colombia 18
JP - Giappone 18
NL - Olanda 17
IQ - Iraq 16
AT - Austria 14
BE - Belgio 14
CR - Costa Rica 13
MY - Malesia 13
PK - Pakistan 13
UZ - Uzbekistan 13
EC - Ecuador 12
PR - Porto Rico 12
CL - Cile 11
TT - Trinidad e Tobago 11
ES - Italia 10
TN - Tunisia 10
CW - ???statistics.table.value.countryCode.CW??? 9
PH - Filippine 9
DZ - Algeria 8
SA - Arabia Saudita 8
SV - El Salvador 8
VE - Venezuela 8
GT - Guatemala 7
JM - Giamaica 7
PY - Paraguay 7
EG - Egitto 6
IE - Irlanda 6
MA - Marocco 6
NI - Nicaragua 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
EE - Estonia 5
GP - Guadalupe 5
HN - Honduras 5
JO - Giordania 5
LT - Lituania 5
PE - Perù 5
TH - Thailandia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
IL - Israele 4
KE - Kenya 4
PA - Panama 4
SY - Repubblica araba siriana 4
BB - Barbados 3
GE - Georgia 3
HR - Croazia 3
LB - Libano 3
NP - Nepal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
BO - Bolivia 2
BW - Botswana 2
CG - Congo 2
KR - Corea 2
MM - Myanmar 2
PS - Palestinian Territory 2
ZW - Zimbabwe 2
AM - Armenia 1
AU - Australia 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
Totale 10.068
Salva come PNG Salva come JPEG
Città #
Ashburn 565
Fairfield 421
Singapore 383
San Jose 313
Chandler 311
Woodbridge 263
Houston 258
Hong Kong 251
Milan 217
Bari 211
Jacksonville 209
Ann Arbor 189
Nyköping 186
Cambridge 184
Seattle 180
Wilmington 168
Beijing 140
Council Bluffs 104
Rome 92
Nanjing 72
New York 71
Lauterbourg 69
Roxbury 63
Boardman 60
Lawrence 60
Los Angeles 57
Dallas 50
Santa Clara 46
Ho Chi Minh City 43
Des Moines 42
Princeton 36
Helsinki 34
Inglewood 34
Columbus 30
Hanoi 30
Phoenix 28
Moscow 27
São Paulo 25
Buffalo 24
Dearborn 23
Brooklyn 22
London 22
Jakarta 21
Montreal 20
Pune 20
Falkenstein 19
Shenyang 19
Turin 19
Abidjan 18
Orem 18
Tokyo 18
Warsaw 18
Chicago 17
San Diego 17
Frankfurt am Main 16
Munich 16
Paris 16
Atlanta 15
Belo Horizonte 14
Dong Ket 14
Rio de Janeiro 14
Brussels 13
Haiphong 13
Noicattaro 13
Tashkent 13
Chennai 11
Figino 11
Guangzhou 11
Nanchang 11
San Francisco 11
Amsterdam 10
Naples 10
Nuremberg 10
The Dalles 10
Tianjin 10
Toronto 10
Boston 9
Hebei 9
Willemstad 9
Ankara 8
Denver 8
Johannesburg 8
Mexico City 8
Stockholm 8
Vienna 8
Washington 8
Changsha 7
Guatemala City 7
Newark 7
Poplar 7
San José 7
Shanghai 7
Campinas 6
Charlotte 6
Dublin 6
Fortaleza 6
Indiana 6
Jiaxing 6
Kuala Lumpur 6
Managua 6
Totale 6.282
Salva come PNG Salva come JPEG
Nome #
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 778
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 232
ANTIBODIES TO ENDOPLASMIN AND THEIR USE 212
Methods for treating a tumor using an antibody that specifically binds HMW-MAA 205
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 203
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 195
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 186
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 186
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 178
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 175
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 174
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 165
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 163
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 153
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 153
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 152
Rheumatic disorders as paraneoplastic syndromes 148
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 144
Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer 144
CD20: A target antigen for immunotherapy of autoimmune diseases 142
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 139
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 137
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 136
The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells 133
Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report 133
Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis. 132
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 131
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 130
Endothelial cells in tumor microenvironment: insights and perspectives 128
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 128
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 128
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 127
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 126
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 123
Novel combinatorial therapy for pancreatic adenocarcinoma 123
CSPG4 in cancer: Multiple roles 121
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors 120
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 119
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 115
Insight into the specificità of the anti-CD20 monclonal antibody Rituximab. 114
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 109
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 108
Characterization of the specificity of the Human scFv W9 108
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 107
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence 107
Circulating Inhibitory Factor 1 levels in adult patients with Prader-Willi syndrome 106
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS 105
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4 103
AUTO-ANTIBODIES TO THE AMINO TERMINAL SEGMENT (AMINOACID 1-17) OF CENP-A DISPLAY A UNIQUE SPECIFICITY IN SYSTEMIC SCLEROSIS AND ARE INDEPENDENTLY EXPRESSED FROM THOSE AGAINST CENP-B 103
Raynaud’s phenomenon: from molecular pathogenesis to therapy 101
Targeting cancer initiating cells in pancreatic adenocarcinoma 100
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN MONOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS AND CORRELATION WITH THEIR SEROLOGICAL PROFILE 99
Harnessing host innate immunity may combat acquired resistance to BRAFi 99
Peptidi che mimano l'antigene CD20: potenzialità terapeutiche nel lupus eritematoso sistemico 96
Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity 95
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope 93
Ruolo degli autoanticorpi nelle patologie autoimmuni 90
Metodo ELISA: dosaggio della catena pesante della molecola HLA non associata alla b2-microglobulina 88
Chronic-Relapsing cutaneous leukocytoclastic vasculitis in a young patient with reduced EBV-specific T cell response using enzyme-linked immunospot (ELISPOT) assay successfully treated with Valaciclovir 88
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity 88
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides. Journal of Immunology 86
Phlegmonous abscess associated with etanercept therapy 86
Ruolo degli autoanticorpi nelle patologie autoimmuni 85
Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study 81
Poems syndrome with amyloidosis and calchyphylaxis.A case report 79
Two structurally different peptides mimic a CD20 epitope recognized by rituximab 79
null 78
Quantitative evaluation of anti-FOXE-3 Ab identifies a subset of anti-CENP positive systemic sclerosis patients who are less prone to develop active disease 78
Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces 78
Functional characterization of peptides mimicking the CD20 epitope recognized by Rituximab 77
 Peptides highly specific to the variable region of TNF-ALFA-specific references licensed (RL) monoclonal antibodies (MAB), as potential tool to effectively assess similarity between biosimilars and the correspondig RL MAB 73
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 72
Generation of linear and cyclic peptides revealed a unique fine specificity of Rituximab and its possible cross-reactivity with an acid sphingomyelinase-like phosphodiesterasem 3B precursor 71
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 70
Mimotope peptides in the immunization against CD20: a promising approach to the therapy of autoimmune diseases 63
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 57
Methods for treating a tumor using an antibody that specifically binds grp94 54
Classic pyoderma gangrenosum 54
null 49
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 46
β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 43
Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 39
Barriers to therapy adherence in a group of Italian patients with systemic lupus erythematosus 38
Functional characterization of peptides mimicking the CD-20 epitope recognized by Rituximab 36
null 33
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma 29
Clinical associations and related factors of metabolic syndrome in systemic sclerosis: results from an observational multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 21
Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross‐Sectional Study of 96 Italian Patients 19
Inflammatory biomarkers of atherosclerosis in SLE that may improve SLE-specific cardiovascular risk assessment tools 19
Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients 16
Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational “real‑life” GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 14
Totale 10.347
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022407 0 0 0 0 22 34 51 22 32 23 97 126
2022/2023844 122 94 45 74 107 105 29 116 113 9 16 14
2023/2024363 24 53 19 70 21 77 11 21 8 8 6 45
2024/20251.280 79 18 114 20 28 86 158 106 53 67 178 373
2025/20263.707 396 159 181 374 307 170 354 93 934 255 82 402
2026/2027950 106 150 224 459 11 0 0 0 0 0 0 0
Totale 10.347